达比加群在终末期肝病合并急性肾损伤患者中的逆转
本文报告一例终末期肝病患者在服用达比加群150mg每日两次期间发生危及生命的出血和急性肾损伤。尽管使用了特异性逆转剂伊达鲁珠单抗,仍未实现止血,其他治疗及血液透析通路建立均失败。提示终末期肝病患者使用达比加群应谨慎并减量。
要点
- 终末期肝病患者使用达比加群出血风险高,应谨慎并减量。
- 达比加群主要经肾清除,肾功能下降时易蓄积增加出血风险。
- 伊达鲁珠单抗在严重肝病合并AKI患者中可能无法有效止血。
核心结论
- 终末期肝病患者使用达比加群应谨慎并采用减低的剂量。
研究设计与样本
- 本文为病例报告,报告一例终末期肝病患者服用达比加群150mg每日两次后发生危及生命的出血和急性肾损伤。
主要发现
- 患者服用达比加群150mg每日两次期间发生危及生命的出血和急性肾损伤。
- 给予伊达鲁珠单抗后未能实现止血。
- 给予维生素K、新鲜冰冻血浆、去氨加压素、奥曲肽和泮托拉唑未止住出血或影响凝血参数。
- 无法建立血液透析的血管通路。
临床怎么用
- 终末期肝病患者处方达比加群时应谨慎并考虑减量。
局限性
- 本文为单例病例报告,结论基于个案经验,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dabigatran, a direct thrombin inhibitor and one of the new class of direct oral anticoagulants, is increasingly used in preference to warfarin because of its efficacy and ease of administration. However, because the drug is cleared by the kidneys, it can accumulate in plasma and increase the risk for bleeding in patients with decreased kidney function. We report a patient with end-stage liver disease who developed life-threatening hemorrhage and acute kidney injury while taking dabigatran, 150mg, twice daily. Although the patient received idarucizumab, an anti-dabigatran antibody fragment used as an antidote, hemostasis could not be achieved. Administration of vitamin K, fresh frozen plasma, desmopressin, octreotide, and pantoprazole did not arrest bleeding or affect coagulation parameters, and it was not possible to establish vascular access for hemodialysis. In patients with end-stage liver disease, who are at increased risk for both bleeding and acute kidney injury, dabigatran should be prescribed cautiously and at decreased dose.
引用
- Novak JE, Alamiri K, Yee J, et al. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury. Am J Kidney Dis. 2017. PMID: 28549534. doi:10.1053/j.ajkd.2017.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。